Brief: Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F For Treatment Of Refractory Systemic Lupus Erythematosus (Sle)
15/05/2023 12:11
May 15 (Reuters) - Gracell Biotechnologies Inc GRCL.O :
* GRACELL BIOTECHNOLOGIES INITIATES INVESTIGATIONAL STUDY
EVALUATING GC012F FOR TREATMENT OF REFRACTORY SYSTEMIC LUPUS
ERYTHEMATOSUS (SLE)
Source text for Eikon: ID:nPn531L0Ma
Further company coverage: GRCL.O
Recent news on Gracell Biotechnologies
See all newsBrief: Gracell Biotechnologies Announces Shareholders’ Approval Of Merger Agreement
Brief: Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Newscasts - UK Day Ahead: European shares start last week of 2023 on strong footing
Live Markets: European futures rise after holiday break
Press Digest: British Business - Dec 27